Skip to main content
Erschienen in: Medical Oncology 1/2009

01.03.2009 | Original Paper

Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients

verfasst von: Nuray Buyukberber, Süleyman Buyukberber, Alper Sevinc, Celalettin Camci

Erschienen in: Medical Oncology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Assay of cytokines and C reactive protein (CRP) in different periods of febrile neutropenia may be helpful for early defining the risk in severe infections. We determined serum interleukin-6 (IL-6), interleukin-8 (IL-8), soluble interleukin-2 receptor (sIL-2R), tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and CRP in 22 previously untreated patients with various malignancies. Samples were obtained in four different clinical periods of febrile neutropenia; prior to chemotherapy, afebrile neutropenic period after chemotherapy, febrile neutropenic period, and recovery period. When compared to sex-and age-matched group of healthy subjects, IL-6, IL-8, sIL-2R, and CRP levels were found to be elevated in all periods. The highest levels were encountered in the febrile neutropenic period. For predictivity purposes, the afebrile neutropenic period was the most important period. Serum sIL-2R, IL-6, IL-8 and CRP levels were elevated in this period. IL-8 levels showed the most stable elevation through different stages of febrile neutropenia. Serum IL-8 levels were found to have the most reliable and stable elevation in different clinical stages of febrile neutropenia. Nevertheless, IL-8 is not able to discriminate among risk groups and cannot be used as a predictive factor.
Literatur
1.
Zurück zum Zitat Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol. 1994;12:107–14.PubMed Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol. 1994;12:107–14.PubMed
2.
4.
Zurück zum Zitat Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999;86:126–34. doi :10.1002/(SICI)1097-0142(19990701)86:1<126::AID-CNCR18>3.0.CO;2-1.PubMedCrossRef Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999;86:126–34. doi :10.1002/(SICI)1097-0142(19990701)86:1<126::AID-CNCR18>3.0.CO;2-1.PubMedCrossRef
7.
Zurück zum Zitat Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10:316–22.PubMed Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10:316–22.PubMed
8.
Zurück zum Zitat Klaassen RJ, Goodman TR, Pham B, Doyle JJ. ‘Low-risk’ prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012–9.PubMed Klaassen RJ, Goodman TR, Pham B, Doyle JJ. ‘Low-risk’ prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012–9.PubMed
10.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.PubMed Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.PubMed
12.
Zurück zum Zitat Lehrnbecher T, Venzon D, de Haas M, Chanock S, Kuhl J. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis. 1999;29:414–9. doi:10.1086/520224.PubMedCrossRef Lehrnbecher T, Venzon D, de Haas M, Chanock S, Kuhl J. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis. 1999;29:414–9. doi:10.​1086/​520224.PubMedCrossRef
14.
Zurück zum Zitat Herrmann JL, Blanchard H, Brunengo P, Lagrange PH. TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values. Infection. 1994;22:309–15. doi:10.1007/BF01715533.PubMedCrossRef Herrmann JL, Blanchard H, Brunengo P, Lagrange PH. TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values. Infection. 1994;22:309–15. doi:10.​1007/​BF01715533.PubMedCrossRef
15.
Zurück zum Zitat Engervall P, Granstrom M, Andersson B, Bjorkholm M. Monitoring of endotoxin, interleukin-6 and C-reactive protein serum concentrations in neutropenic patients with fever. Eur J Haematol. 1995;54:226–34.PubMed Engervall P, Granstrom M, Andersson B, Bjorkholm M. Monitoring of endotoxin, interleukin-6 and C-reactive protein serum concentrations in neutropenic patients with fever. Eur J Haematol. 1995;54:226–34.PubMed
17.
Zurück zum Zitat Pechumer H, Wilhelm M, Ziegler-Heitbrock HW. Interleukin-6 levels in febrile children during maximal aplasia after bone marrow transplantation are similar to those in children with normal hematopoiesis. Ann Hematol. 1995;70:309–12. doi:10.1007/BF01696617.PubMedCrossRef Pechumer H, Wilhelm M, Ziegler-Heitbrock HW. Interleukin-6 levels in febrile children during maximal aplasia after bone marrow transplantation are similar to those in children with normal hematopoiesis. Ann Hematol. 1995;70:309–12. doi:10.​1007/​BF01696617.PubMedCrossRef
19.
Zurück zum Zitat de Bont ES, Vellenga E, Swaanenburg JC, Fidler V, Visser-van Brummen PJ, Kamps WA. Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol. 1999;107:375–80. doi:10.1046/j.1365-2141.1999.01707.x.PubMedCrossRef de Bont ES, Vellenga E, Swaanenburg JC, Fidler V, Visser-van Brummen PJ, Kamps WA. Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol. 1999;107:375–80. doi:10.​1046/​j.​1365-2141.​1999.​01707.​x.PubMedCrossRef
20.
Zurück zum Zitat Stryjewski GR, Nylen ES, Bell MJ, Snider RH, Becker KL, Wu A, et al. Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med. 2005;6:129–35. doi:10.1097/01.PCC.0000149317.15274.48.PubMedCrossRef Stryjewski GR, Nylen ES, Bell MJ, Snider RH, Becker KL, Wu A, et al. Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med. 2005;6:129–35. doi:10.​1097/​01.​PCC.​0000149317.​15274.​48.PubMedCrossRef
21.
Zurück zum Zitat Engel A, Mack E, Kern P, Kern WV. An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection. 1998;26:213–21.PubMedCrossRef Engel A, Mack E, Kern P, Kern WV. An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection. 1998;26:213–21.PubMedCrossRef
22.
Zurück zum Zitat Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol. 2000;111:1093–102. doi:10.1046/j.1365-2141.2000.02458.x.PubMedCrossRef Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol. 2000;111:1093–102. doi:10.​1046/​j.​1365-2141.​2000.​02458.​x.PubMedCrossRef
23.
Zurück zum Zitat Kern WV, Heiss M, Steinbach G. Prediction of Gram-negative bacteremia in patients with cancer and febrile neutropenia by means of ınterleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis. 2001;32:832–5. doi:10.1086/319207.PubMedCrossRef Kern WV, Heiss M, Steinbach G. Prediction of Gram-negative bacteremia in patients with cancer and febrile neutropenia by means of ınterleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis. 2001;32:832–5. doi:10.​1086/​319207.PubMedCrossRef
25.
Zurück zum Zitat Heney D, Lewis IJ, Evans SW, Banks R, Bailey CC, Whicher JT. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis. 1992;165:886–90.PubMed Heney D, Lewis IJ, Evans SW, Banks R, Bailey CC, Whicher JT. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis. 1992;165:886–90.PubMed
26.
Zurück zum Zitat Engel A, Kern WV, Mürdter G, Kern P. Kinetics and correlation with body temperature of circulating interleukin-6, interleukin-8, tumour necrosis factor alpha and interleukin-1 beta in patients with fever and neutropenia. Infection. 1994;2:160–3. doi:10.1007/BF01716695.CrossRef Engel A, Kern WV, Mürdter G, Kern P. Kinetics and correlation with body temperature of circulating interleukin-6, interleukin-8, tumour necrosis factor alpha and interleukin-1 beta in patients with fever and neutropenia. Infection. 1994;2:160–3. doi:10.​1007/​BF01716695.CrossRef
27.
Zurück zum Zitat von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23:539–44. doi:10.1007/s10096-004-1156-y.CrossRef von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23:539–44. doi:10.​1007/​s10096-004-1156-y.CrossRef
29.
Zurück zum Zitat Katz JA, Mustafa MM, Bash RO, Cash JV, Buchanan GR. Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer. Pediatr Infect Dis. 1992;11:708–12.CrossRef Katz JA, Mustafa MM, Bash RO, Cash JV, Buchanan GR. Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer. Pediatr Infect Dis. 1992;11:708–12.CrossRef
30.
Zurück zum Zitat Manian FA. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin Infect Dis. 1995;21:114–21.PubMed Manian FA. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin Infect Dis. 1995;21:114–21.PubMed
31.
Zurück zum Zitat Lindemann A, Tamm I, Tanodi K, Mertelsmann R. Interleukin-8 serum levels for early detection of infections episodes in neutropenic patients. J Infect Dis. 1995;172:610–3.PubMed Lindemann A, Tamm I, Tanodi K, Mertelsmann R. Interleukin-8 serum levels for early detection of infections episodes in neutropenic patients. J Infect Dis. 1995;172:610–3.PubMed
32.
Zurück zum Zitat Schonbohn H, Schuler M, Kolbe K, Peschel C, Huber C, Bemb W, et al. Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-R A during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. Ann Hematol. 1995;71:161–8. doi:10.1007/BF01910312.PubMedCrossRef Schonbohn H, Schuler M, Kolbe K, Peschel C, Huber C, Bemb W, et al. Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-R A during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. Ann Hematol. 1995;71:161–8. doi:10.​1007/​BF01910312.PubMedCrossRef
35.
Zurück zum Zitat Persson L, Engervall P, Magnuson A, Vikerfors T, Söderquist B, Hansson LO, et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis. 2004;36:365–71. doi:10.1080/00365540410020217.PubMedCrossRef Persson L, Engervall P, Magnuson A, Vikerfors T, Söderquist B, Hansson LO, et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis. 2004;36:365–71. doi:10.​1080/​0036554041002021​7.PubMedCrossRef
36.
Zurück zum Zitat Erten N, Genc S, Besisik SK, Saka B, Karan MA, Tascioglu C. The predictive and diagnostic values of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients. J Chin Med Assoc. 2004;67:217–21.PubMed Erten N, Genc S, Besisik SK, Saka B, Karan MA, Tascioglu C. The predictive and diagnostic values of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients. J Chin Med Assoc. 2004;67:217–21.PubMed
37.
Zurück zum Zitat Persson L, Söderquist B, Engervall P, Vikerfors T, Hansson LO, Tidefelt U. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol. 2005;74:297–303. doi:10.1111/j.1600-0609.2004.00387.x.PubMedCrossRef Persson L, Söderquist B, Engervall P, Vikerfors T, Hansson LO, Tidefelt U. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol. 2005;74:297–303. doi:10.​1111/​j.​1600-0609.​2004.​00387.​x.PubMedCrossRef
38.
Zurück zum Zitat Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51. doi:10.1086/339215.PubMedCrossRef Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51. doi:10.​1086/​339215.PubMedCrossRef
Metadaten
Titel
Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients
verfasst von
Nuray Buyukberber
Süleyman Buyukberber
Alper Sevinc
Celalettin Camci
Publikationsdatum
01.03.2009
Verlag
Humana Press Inc
Erschienen in
Medical Oncology / Ausgabe 1/2009
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-008-9081-z

Weitere Artikel der Ausgabe 1/2009

Medical Oncology 1/2009 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.